Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

MIDCAB Versus DES in Proximal LAD Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00299429
Recruitment Status : Completed
First Posted : March 6, 2006
Last Update Posted : June 26, 2018
Sponsor:
Collaborator:
Cordis Medizinische Apparate GmbH
Information provided by (Responsible Party):
University of Leipzig

Brief Summary:
Percutaneous coronary intervention with a sirolimus-coated stent compared to minimally invasive bypass surgery in patients with isolated proximal left anterior descending coronary arteries in terms of non-inferiority of an end point combining mortality, acute myocardial infarction and rate of reintervention of the target vessel within one year.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Procedure: Stenting and minimally invasive bypass surgery Procedure: PCI with DES Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Comparison of Minimally Invasive Direct Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention With Drug-eluting Stents in Patients With Proximal Stenosis of the Left Anterior Descending Coronary Artery
Study Start Date : January 2003
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Arm Intervention/treatment
Active Comparator: MIDCAB Surgery
MIDCAB Surgery
Procedure: Stenting and minimally invasive bypass surgery
Experimental: PCI with drug-eluting stent
PCI with DES
Procedure: PCI with DES
PCI with DES




Primary Outcome Measures :
  1. Major adverse cardiac events [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Perioperative complications [ Time Frame: 30 days ]
  2. CCS-Classification [ Time Frame: 12 months ]
  3. cost-effectiveness [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Single-vessel disease of the proximal LAD with a stenosis > 50% (multivessel disease only if further coronary vessel stenoses do not require treatment)
  2. Patients with angina pectoris (CCS 1-4)
  3. Asymptomatic patients if clear signs of ischemia in the segments supplied by the LAD as assessed by bicycle ergometry or treadmill and/or scintigraphically and/or stress echo
  4. Patients for whom both methods of treatment are equally possible
  5. Consensus between the cardiac surgeon and the cardiologist that both inclusion and exclusion criteria are met in the selected case
  6. Informed consent of the patient.

Exclusion Criteria:

  1. Patients < 18 years
  2. Pregnancy
  3. Previous coronary artery bypass surgery
  4. Concomitant diseases that lead to a greater risk for each of the treatment strategies
  5. Significant peripheral arterial occlusive disease
  6. Concomitant disease with limited life expectancy (e.g. malignant tumours that have not been curatively treated)
  7. Objective follow-up examination not possible due to physical or mental handicap
  8. Participation in another study.

Angiographical exclusion criteria:

  1. Left main stem stenosis
  2. Multivessel disease for which surgical or interventional therapy on other vessel areas is required.
  3. Diagonal/septal branch > 1.5 mm, which might be compromised by a stent
  4. Need for acute intervention (e.g. acute myocardial infarction)
  5. Total occlusion of the LAD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00299429


Locations
Layout table for location information
Germany
University of Leipzig - Heart Center
Leipzig, Germany, 04289
Sponsors and Collaborators
University of Leipzig
Cordis Medizinische Apparate GmbH
Investigators
Layout table for investigator information
Principal Investigator: Holger Thiele, MD Heart Center Leipzig - University Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Leipzig
ClinicalTrials.gov Identifier: NCT00299429    
Other Study ID Numbers: 2-Thiele
First Posted: March 6, 2006    Key Record Dates
Last Update Posted: June 26, 2018
Last Verified: March 2007
Keywords provided by University of Leipzig:
Stent
drug-eluting stent
Minimally invasive bypass surgery
left anterior descending
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases